LENZ — LENZ Therapeutics, Inc.

LENZ Therapeutics holds the first FDA-approved aceclidine eye drop for presbyopia — a clinically superior product in a category that its predecessor, AbbVie's Vuity, launched with full commercial force in 2021 and grew to only $257 million in seven major markets over three years, far below initial expectations; the market is pricing VIZZ at essentially zero value above the company's $324 million cash balance, which is either the right price for a business in a category that has proven resistant to pharmaceutical adoption or a significant misvaluation of a better product in a market that is still learning the category exists. Interesting but requires a specific catalyst — meaningful quarterly prescription acceleration and sustained refill rates demonstrating that the behavioral barrier of "just buy reading glasses" is being overcome — to be actionable.

---

Presbyopia — the gradual loss of near-focus that begins in the mid-forties and affects virtually every human being who lives past fifty — is the most prevalent age-related condition on earth that most people have decided to manage with a hardware purchase rather than a medical intervention. The reading glasses sitting on approximately 128 million Americans represent not a solved problem but an accepted inconvenience: a nuisance that is cheap to manage, easily purchased at a drugstore without a prescription, and never quite uncomfortable enough to drive most sufferers to a physician's office. That behavioral equilibrium has kept presbyopia from becoming a pharmaceutical market in any meaningful sense for the first sixty years of the modern pharmaceutical era, despite the enormous theoretical addressable population.

The emergence of prescription presbyopia eye drops since 2021 represents the first serious pharmaceutical challenge to that equilibrium. The thesis is not that drops are better than glasses — for many patients they are not — but that a segment of the presbyopic population finds the glasses alternative annoying enough, and values the aesthetics and convenience of correction-free near vision enough, to fill a monthly prescription at roughly eighty dollars. Finding that segment, convincing them to try drops, and converting enough of them to monthly refills to build a sustainable commercial business: this is the specific task that LENZ Therapeutics has embarked upon with VIZZ, and it is the task on which the investment case rises or falls.

The ophthalmic pharmaceutical market is structurally attractive compared to most specialty pharma categories. Prescribers are concentrated — roughly 45,000 to 50,000 ophthalmologists and optometrists in the United States represent the entire gating channel for any new prescription ophthalmic therapy — which makes commercial launch economics efficient. A sales force that reaches 15,000 to 20,000 ECPs has essentially covered the relevant prescriber universe. Payer dynamics in ophthalmology are moderately favorable; commercial insurance typically covers brand-name ophthalmic agents with patient assistance programs bridging the gap for uninsured patients. The challenge in presbyopia specifically is that the condition is not painful, not visually disabling in the way that glaucoma or macular degeneration are, and offers a functional if aesthetically imperfect alternative in the form of over-the-counter glasses that costs a fraction of a prescription.

Vuity, pilocarpine HCl 1.25% (AbbVie), launched in November 2021 as the first and only prescription drop for presbyopia, wrote the first chapter of what the market actually looks like rather than what the TAM calculations suggest. AbbVie deployed a substantial commercial organization behind the launch — the same salesforce infrastructure that supports an ophthalmology portfolio including Restasis and Ozurdex — achieved initial awareness among eye care professionals, and generated approximately $60–80 million in U.S. annual net revenues after the first full year. By 2023, Vuity had reached roughly $257 million in seven major markets combined. That figure is real commercial traction. It is also substantially below the billion-dollar peak sales projections that circulated at launch. The gap between the $5 billion-plus TAM that derives from counting 128 million presbyopic Americans and the $257 million that the first approved drug actually collected tells the analyst something important about the behavioral conversion rate from "presbyopic person who wears reading glasses" to "patient who fills a monthly prescription." The conversion rate is low. And Vuity was the only drop available for more than two years.

LENZ Therapeutics received FDA approval for VIZZ (aceclidine ophthalmic solution 1.44%) on July 31, 2025, making it the first and only approved aceclidine-based presbyopia treatment — a mechanistic distinction from the pilocarpine-based Vuity and Qlosi (Orasis Pharmaceuticals' pilocarpine 0.4%, launched early 2025) that matters because the clinical profile is genuinely different. Aceclidine is a selective muscarinic agonist that produces a smaller pupil diameter under treatment — approximately 1.8 millimeters median — versus pilocarpine's 2.7 to 3 millimeters. The smaller miosis means less distance vision blur and fewer photophobia side effects; the mechanism also produces a longer treatment duration of approximately 10 hours versus Vuity's 6 to 8 hours. The Phase 3 clinical trials demonstrated 93% of VIZZ patients achieving ≥15 letters of near vision improvement versus approximately 85% for Vuity in its pivotal trials. These are not trivial differences. A prescriber who has observed pilocarpine side effects — halos, dim vision, headache — in Vuity patients has a clinically valid reason to try aceclidine.

The competitive landscape VIZZ launched into is crowded relative to the opportunity it is entering. Vuity is established and has a four-year prescribing history with ECPs who have formed opinions about which patients do and do not do well on it. Qlosi (pilocarpine 0.4%, lower concentration, milder effect) launched in early 2025. Brimochol PF (carbachol 2.75% plus brimonidine 0.1%, Tenpoint Therapeutics) received FDA approval in January 2026. The presbyopia drop category now has four approved products and at least two more molecules in pipeline development. This fragmentation is atypical for ophthalmic pharmaceutical markets and it reflects the commercial opportunity the category represents — but it also means that VIZZ must differentiate from three existing approved products rather than simply capturing a monopoly market. The differentiation argument — aceclidine's better side effect profile and longer duration — is clinically sound. Whether it translates to commercial displacement of established prescribing habits is the unanswered question.

Product	Company	Mechanism	Duration	Efficacy (≥15 letters)	Launched
Vuity	AbbVie	Pilocarpine 1.25%	~6–8 hrs	~85%	Nov 2021
Qlosi	Orasis	Pilocarpine 0.4%	~4–6 hrs	~77%	Early 2025
Brimochol PF	Tenpoint	Carbachol + Brimonidine	~8 hrs	~88%	Jan 2026
VIZZ	LENZ	Aceclidine 1.44%	~10 hrs	~93%	Oct 2025

VIZZ's clinical superiority in this table is genuine. Across duration, efficacy, and the indirect measure of side effect profile (smaller miosis → less distance blur), the product compares favorably to every approved competitor. The question the table cannot answer is whether eye care professionals and their patients will act on those differences. Prescribers who have already built experience with Vuity have patients who are refilling (or not), have a pricing infrastructure in place, and have developed prescribing criteria for which patients benefit from drops. Convincing those prescribers to switch their existing patients to VIZZ, or to route new candidates to VIZZ specifically, requires either a meaningful patient preference or a compelling patient failure on existing drugs. The case is plausible. The evidence is not yet sufficient to call it demonstrated.

LENZ reported approximately $1.6 million in net product revenue from VIZZ in Q4 2025, its first full commercial quarter. Over 20,000 prescriptions were filled through the end of Q4, across more than 6,500 unique prescribing eye care professionals. More than 55% of prescribing ECPs wrote multiple prescriptions during the quarter. Broad retail and epharmacy distribution was established by mid-November 2025. The company launched a direct-to-consumer campaign in January 2026 featuring Sarah Jessica Parker, targeting the demographic of adults over 45 who are presbyopic and open to a pharmaceutical alternative to reading glasses.

The $1.6 million quarterly revenue figure requires context to interpret. Twenty thousand prescriptions at VIZZ's $79 monthly price point implies a gross revenue in the range of $1.58 million — the net revenue figure suggests relatively modest gross-to-net adjustments at this early stage, which is consistent with a launch period when copay assistance programs are in effect to reduce patient out-of-pocket costs. The more analytically important figure is what 20,000 total prescriptions in the first quarter implies about the monthly run rate: roughly 6,700 prescriptions per month, rising over the course of the quarter as distribution expanded and awareness grew. For comparison, Vuity achieved approximately 100,000 to 150,000 prescriptions in its first commercial quarter — a figure supported by AbbVie's established commercial presence and the initial novelty of being the first approved presbyopia drop. LENZ's smaller commercial apparatus and the more competitive category environment explain the gap in absolute prescription volume; whether VIZZ's growth trajectory will follow or exceed Vuity's subsequent ramp is the central unknown.

The 55% repeat prescribing rate among ECPs in Q4 is the single most interesting data point in the launch metrics. An eye care professional who has written a second VIZZ prescription — in the same quarter the product launched — has found at least one patient who came back requesting a refill, or has had a new patient presentation that prompted a repeat try. This is genuine physician adoption signal, distinct from the "write one prescription to try the new product" behavior that inflates prescriber counts in early launches without reflecting durable commercial adoption. Whether this figure holds in Q1 2026 and beyond, when the novelty effect has dissipated and the patient cohorts who initially filled prescriptions have either renewed or not, is the measurement that will tell the analyst whether VIZZ is building a refill base or generating a large one-time trial event.

The financial structure of LENZ at this stage is defined entirely by its balance sheet rather than its income statement. As of September 30, 2025, the company held approximately $324 million in cash and marketable securities — raised via a $123 million offering in 2025 specifically to fund the VIZZ commercial launch. Planned commercial spending for 2026 is $80 to $100 million, implying the company will exit 2026 with roughly $220 to $240 million in cash at a minimum, assuming the revenue trajectory does not approach profitability. Research and development expenses add incremental burn. The company is not profitable and will not be profitable in 2026 on any reasonable scenario; the question is whether the launch data by end of 2026 justifies the capital required to continue and whether the trajectory supports accessing additional capital on favorable terms if needed.

The management team has limited publicly established track record in the pharmaceutical commercial context because the company is in its first commercial year. What can be evaluated is the construction of the launch: broad distribution established rapidly, a consumer brand campaign with genuine cultural recognition (Sarah Jessica Parker is a natural fit for the presbyopia demographic), and a clinical positioning that leads with differentiation rather than simply announcing a new product in an existing category. The decision to submit a Marketing Authorization Application to the European Medicines Agency in March 2026 — expanding the regulatory infrastructure in parallel with the U.S. launch — suggests management is thinking about the business at scale rather than treating VIZZ as solely a domestic opportunity. The international licensing partnerships already established in Greater China, South Korea, Southeast Asia, Canada, and the Middle East provide upfront capital and milestone payments that reduce the funding burden of international commercialization.

The growth runway for VIZZ depends on two distinct adoption mechanisms working in sequence. The first is physician adoption — ECPs incorporating VIZZ into their clinical practice as either a primary or secondary choice for presbyopia candidates. The second is patient retention — the behavioral change that must occur for patients to choose a monthly $79 prescription over a $20 pair of reading glasses from CVS. The physician adoption signal from Q4 2025 is encouraging: 6,500 unique prescribers in the first quarter represents a meaningful early footprint, and the 55% repeat prescribing rate suggests this is not purely a curiosity wave. Patient retention is the unknown.

Quarter	Total Rxs (cumulative)	Net Revenue ($M)	Unique Prescribers	Repeat Prescribing Rate
Q4 2025 (VIZZ launch)	20,000+	$1.6	6,500+	55%+
Q1 2026	TBD	TBD	TBD	TBD
Q2 2026	TBD	TBD	TBD	TBD

The table above is the investment thesis as a set of blanks to be filled in. The blanks that matter most are not the absolute prescription counts but the sequential quarterly trajectory: is Q1 2026 prescription volume materially above Q4 2025? Is the prescriber count growing as the DTC campaign generates patient pull? Are the patients who filled a first prescription in October and November 2025 refilling in January and February 2026? These are the numbers that will tell the analyst whether VIZZ is building the refill base that justifies its commercial investment or whether, like Vuity's initial launch, it is generating physician interest without translating that interest into a sustainable patient behavior change.

The penetration argument is simultaneously the most compelling and the most dangerous aspect of the thesis. Presbyopia affects approximately 128 million Americans as of 2026. VIZZ, even at 20,000 prescriptions total across its entire launch period, has reached substantially less than 0.1% of that population. If even 1% of presbyopic Americans chose prescription drops as a primary vision management strategy, the addressable market at $79 monthly would represent approximately $1.2 billion in annual U.S. retail pharmacy revenue. The problem with this arithmetic is that Vuity has been available for four years, reached essentially 100% of the prescribing ECP community in the U.S., and is generating revenue that implies a sub-0.5% adoption rate of the presbyopic population. The TAM is not converting to revenue at the rate the calculation suggests, and there is no structural reason to expect that VIZZ, entering a market that now has four competing products, will dramatically accelerate the category conversion rate that Vuity could not move.

At $10.48 per share with approximately 31.3 million shares outstanding, LENZ's market capitalization is approximately $328 million. Against $324 million in cash, the market is assigning an implied value of approximately $4 million to the VIZZ asset — an FDA-approved, actively-commercializing pharmaceutical with 6,500 prescribers and a demonstrated first-quarter launch. That is a striking figure. It reflects genuine market skepticism about whether the presbyopia drop category can sustain commercial momentum, a safety concern from the retinal tear adverse event reported in December 2025 that sent the stock down 25%, and the precedent of Vuity's commercial trajectory disappointing the original projections. Whether the market is correct to price VIZZ at essentially zero net of cash, or whether it is deeply mispricing an asset whose clinical superiority will translate to commercial outperformance over the next twelve months, is precisely the unanswered question.

The intelligent bear on LENZ argues that the retinal safety signal is not a statistical coincidence but a mechanistic warning: any drug that constricts the pupil to 1.8 millimeters increases the risk of pupillary block and may exacerbate conditions that lead to retinal tears in a presbyopic population already predisposed to them, and that the real-world safety data gathering over the next 12 to 24 months of commercial use will reveal adverse events that constrain the prescribing population to a narrower, lower-risk subset — reducing the addressable market and the peak sales potential simultaneously. This argument cannot be dismissed. The answer is that the retinal tear rates in presbyopia drug clinical trials have not exceeded the background rate in this age cohort, that VIZZ's smaller pupil effect theoretically reduces certain types of intraocular pressure risk relative to pilocarpine, and that Vuity has been used for four years without a safety recall — but the answer is not a clean rebuttal, and the adverse event database will require monitoring.

The conclusion is conditional. At a market cap essentially equal to cash, with an FDA-approved product actively in commercial launch demonstrating 55%+ repeat prescribing by ECPs in its first quarter, VIZZ has the minimum conditions to generate a material re-rating if the H1 2026 prescription data shows sequential growth above the category baseline Vuity established. If quarterly prescription volume doubles from Q4 2025 to Q2 2026 — approaching 40,000 to 50,000 quarterly prescriptions by mid-year — and refill data confirms patient retention above 50%, VIZZ is not on a trajectory toward another Vuity; it is on a trajectory toward a differentiated category leader. That outcome would justify a market cap substantially above the current $328 million. If Q1 and Q2 2026 data shows flat or declining sequential prescription volumes, the business is Vuity's story retold, and the $4 million implied value of the asset is approximately right.

The stock is priced as though VIZZ has already failed. The data says it has not yet demonstrated success. What happens between those two truths in the next two quarters is the entire investment case.